November 22, 2022 Tags: Plastic Surgery News
This August, the FDA officially approved the use of Juvéderm Volux for jawline enhancement. While Juvéderm Volux isn’t expected to be available until early 2023 for most practices in the United States, our team was able to receive exclusive early access to this newest product because our very own Lori Lankford, N.P., is an expert injector and National Injectable Trainer for the makers of Juvéderm Volux.
Juvéderm Volux is the sixth product to be added to the Juvéderm product line and a much anticipated addition for its ability to add definition and structure to the jawline. Volux is a hyaluronic-acid based injectable and the first of its kind to be specifically formulated for the chin and jawline. In addition to hyaluronic acid, Volux is composed of a small amount of lidocaine, a local anesthetic, for comfort during the procedure, and Allergan Aesthetics’ proprietary VYCROSS® technology. This technology is what makes Volux so effective. By cross-linking hyaluronic acid particles, Juvéderm Volux provides more lift capacity and structure than other products on the market.
For patients that have moderate to severe loss of jawline definition due to aging, Volux reduces the appearance of jowls, adds volume, and creates a sharp, chiseled jawline with natural-looking results. Sculpting the jawline with Juvéderm Volux not only treats recessed chins and facial profiles, it also helps to balance facial features.
We are proud to be one of the first providers already offering Volux in Nashville, Tennessee. If you are interested in reducing the appearance of jowls and defining your jawline, contact our office today to schedule your consultation.
